blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability
Register Forum

2022.02.11

More...
blank News flashes

News Flashes

New version of the European Patent Register – SPC proceedings information in the Unitary Patent Register.

2024-07-24

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register Resource Book
European Patent Register – pocket guide
FAQ - European Patent Register
FAQ - Register Alert
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP3882277

EP3882277 - FUSION PROTEIN AND USE THEREOF [Right-click to bookmark this link]
StatusRequest for examination was made
Status updated on  20.08.2021
Database last updated on 12.08.2024
FormerThe international publication has been made
Status updated on  22.05.2020
Most recent event   Tooltip31.10.2023New entry: Renewal fee paid 
Applicant(s)For all designated states
Hangzhou Sumgen Biotech Co., Ltd.
Room 005, 3rd Floor
Huannuo Building, 1568 South Ring Road
Changhe Street, Binjiang District
Hangzhou, Zhejiang 310051 / CN
For all designated states
Sumgen Mab (Beijing) Biotech Co., Ltd.
Room 501-1
Unit 4, Building 6, No.88 Kechuang 6th Street
Beijing Economic and Technological
Development Zone
Beijing 100176 / CN
[2021/38]
Inventor(s)01 / LV, Ming
Room 005, 3rd Floor Huannuo Building,
1568 South Ring Road Changhe Street
Binjiang District
Hangzhou, Zhejiang 310051 / CN
02 / DING, Xiaoran
Room 005, 3rd Floor Huannuo Building,
1568 South Ring Road Changhe Street
Binjiang District
Hangzhou, Zhejiang 310051 / CN
03 / MIAO, Shiwei
Room 005, 3rd Floor Huannuo Building,
1568 South Ring Road Changhe Street
Binjiang District
Hangzhou, Zhejiang 310051 / CN
04 / TAN, Bin
Room 005, 3rd Floor Huannuo Building,
1568 South Ring Road Changhe Street
Binjiang District
Hangzhou, Zhejiang 310051 / CN
05 / WANG, Xuegong
Room 005, 3rd Floor Huannuo Building,
1568 South Ring Road Changhe Street
Binjiang District
Hangzhou, Zhejiang 310051 / CN
 [2021/38]
Representative(s)Weickmann & Weickmann PartmbB
Postfach 860 820
81635 München / DE
[N/P]
Former [2021/38]Böhm, Brigitte
Weickmann & Weickmann
Patent- und Rechtsanwälte PartmbB
Postfach 860 820
81635 München / DE
Application number, filing date19884036.513.11.2019
[2021/38]
WO2019CN117856
Priority number, dateCN20181135669014.11.2018         Original published format: CN201811356690
[2021/38]
Filing languageZH
Procedural languageEN
PublicationType: A1 Application with search report
No.:WO2020098672
Date:22.05.2020
Language:ZH
[2020/21]
Type: A1 Application with search report 
No.:EP3882277
Date:22.09.2021
Language:EN
[2021/38]
Search report(s)International search report - published on:CN22.05.2020
(Supplementary) European search report - dispatched on:EP05.07.2022
ClassificationIPC:C07K19/00, C07K14/705, C07K16/30, C12N15/62, C12N15/63, C12N5/10, A61K38/17, A61K39/395, A61P35/00, A61P37/00, C07K16/28, A61K39/00
[2022/31]
CPC:
C07K16/2803 (EP,KR,US); C07K16/2896 (EP,KR,US); C07K16/30 (CN,KR,US);
A61P35/00 (EP,CN,KR,US); A61P37/00 (EP); A61P37/02 (CN);
C07K14/705 (EP); C07K14/70503 (EP,CN); C07K14/70596 (EP);
C07K16/2863 (KR,US); C07K16/32 (CN); C12N15/62 (KR);
A61K2039/505 (EP,CN,KR,US); A61K38/00 (EP,US); C07K2317/31 (EP);
C07K2317/565 (KR,US); C07K2317/732 (EP); C07K2317/92 (EP);
C07K2319/00 (EP,CN,KR); C07K2319/21 (EP); C07K2319/22 (EP);
C07K2319/30 (EP,US); C07K2319/33 (EP) (-)
Former IPC [2021/38]C07K19/00, C07K14/705, C07K16/30, C12N15/62, C12N15/63, C12N5/10, A61K38/17, A61K39/395, A61P35/00, A61P37/00
Designated contracting statesAL,   AT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MK,   MT,   NL,   NO,   PL,   PT,   RO,   RS,   SE,   SI,   SK,   SM,   TR [2021/38]
TitleGerman:FUSIONSPROTEIN UND VERWENDUNG DAVON[2021/38]
English:FUSION PROTEIN AND USE THEREOF[2021/38]
French:PROTÉINE DE FUSION ET SON UTILISATION[2021/38]
Entry into regional phase26.05.2021Translation filed 
26.05.2021National basic fee paid 
26.05.2021Search fee paid 
26.05.2021Designation fee(s) paid 
26.05.2021Examination fee paid 
Examination procedure26.05.2021Examination requested  [2021/38]
25.01.2023Amendment by applicant (claims and/or description)
Fees paidRenewal fee
30.06.2021Renewal fee patent year 03
26.10.2022Renewal fee patent year 04
31.10.2023Renewal fee patent year 05
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Documents cited:Search[A]WO2016024021  (MERCK PATENT GMBH [DE]) [A] 1-16 * paragraphs [0005] , [0007] - [0009] - [0018] - [0031] - [0086] - [0090] - [0122] *;
 [A]  - E. C. PICCIONE ET AL, "SIRP -Antibody Fusion Proteins Selectively Bind and Eliminate Dual Antigen-Expressing Tumor Cells", CLINICAL CANCER RESEARCH, US, (20160428), vol. 22, no. 20, doi:10.1158/1078-0432.CCR-15-2503, ISSN 1078-0432, pages 5109 - 5119, XP055467921 [A] 1-16 * abstract * * page 5110, paragraphs SIRPabody construction, expression and purificatio; figure 1 * * page 5112, paragraph Results - page 5115; figure 5 * * page 5118, column l, paragraph 2 *

DOI:   http://dx.doi.org/10.1158/1078-0432.CCR-15-2503
 [A]  - K. WEISKOPF ET AL, "Engineered SIRP Variants as Immunotherapeutic Adjuvants to Anticancer Antibodies", SCIENCE, US, (20130530), vol. 341, no. 6141, doi:10.1126/science.1238856, ISSN 0036-8075, pages 88 - 91, XP055223925 [A] 1 * abstract * * page 90, column l, paragraph 2 - column r, paragraph 2; figure 1 *

DOI:   http://dx.doi.org/10.1126/science.1238856
 [A]  - Laia Pascual Ponce ET AL, "SIRP?-antibody fusion proteins stimulate phagocytosis and promote elimination of acute myeloid leukemia cells", Oncotarget, United States, doi:10.18632/oncotarget.14500, (20170214), pages 11284 - 11301, URL: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5355265/pdf/oncotarget-08-11284.pdf, XP055549877 [A] 1-16 * abstract * * page 11285, column r, paragraphs 2,3; figure 2 * * page 11287, paragraph LicMABs bind to CD33 with high affinity and weakly * * page 11289, paragraph LicMABs mediate speccific lysis of AML cell lines - page 11291 * * page 11292, paragraph LicMABs effeciently promote elimination of primary; figures 6,7 *

DOI:   http://dx.doi.org/10.18632/oncotarget.14500
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.